checkAd
    Startseite > Aktien > Cue Biopharma > Nachrichten
    Cue Biopharma Aktie
    1,8700
     
    USD
    +9,36 %
    +0,1600 USD
    Letzter Kurs 02:00:00 Nasdaq
    1,8700
     
    USD
    100 STK
    Geldkurs 20.05.24
    1,8800
     
    USD
    2.500 STK
    Briefkurs 20.05.24
    ISIN: US22978P1066 · WKN: A2JAT5 · SYM: CUE · USA

    Neueste Nachrichten

    Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
    09.05.24 · globenewswire · Cue Biopharma
    Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
    08.05.24 · globenewswire · Cue Biopharma
    Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
    07.05.24 · globenewswire · Cue Biopharma
    Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    24.04.24 · globenewswire · Cue Biopharma
    Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
    08.04.24 · globenewswire · Cue Biopharma
    Cue Biopharma to Host Business Update Call and Webcast
    02.04.24 · globenewswire · Cue Biopharma
    Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
    29.02.24 · globenewswire · Cue Biopharma
    Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    06.02.24 · globenewswire · Cue Biopharma
    Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
    22.11.23 · globenewswire · Cue Biopharma
    Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
    09.11.23 · globenewswire · Cue Biopharma
    Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
    07.11.23 · globenewswire · Cue Biopharma
    Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
    03.11.23 · globenewswire · Cue Biopharma